Finding Clinical Trials for Triple-Negative Breast Cancer in Black Women: Life Guide

Triple-negative breast cancer (TNBC) is a particularly aggressive variant that lacks estrogen and progesterone receptors along with HER2 protein. Predominantly affecting women under 40, particularly Black women and those with a BRCA1 mutation, TNBC poses treatment challenges. Dr. Michael S. Simon emphasizes the urgency of novel treatments, as relapses are common. Clinical trials offer promising avenues, testing various therapies and aiding advancements. Interested patients should consult oncologists or explore resources like clinicaltrials.gov for potential options, always considering eligibility and inherent risks before participating.